Pair page
Pinealon with Selank
Mechanism-tag overlap and published literature for Pinealon and Selank, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
khavinson-brain-tripeptide-bioregulator
anxiolytic-nootropictuftsin-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Pinealon and Selank have published these mechanism-level observations. Not a co-administration recommendation.
Russian anxiolytic tuftsin-derived peptide. Pinealon + Selank covers cognitive support and anxiolysis in community Russian-peptide protocols.
Quick facts
Pinealon
Selank
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Pinealon | Khavinson V, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834146. PMID 34834146 | systematic review |
| 2021 | Pinealon | Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mikhailova N, Petukhov M. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel). 2021;14(6):515. PMID: 34071714. PMID 34071714 | preclinical, in vivo |
| 2018 | Pinealon | Klement GA, Hawrysh PJ, Khavinson V, Buck LT. Pinealon's effect on hypoxia tolerance in cultured rat pyramidal neurons. Cell Mol Neurobiol. 2018. | preclinical, in vivo |
| 2017 | Pinealon | Khavinson VKh, Lin'kova NS, Kukanova EO. Neuroprotective Effect of EDR Peptide in Mouse Model of Huntington's Disease. J Neurol Neurosci. 2017. (Khavinson group Huntington's publication.) | preclinical, in vivo |
| 2021 | Pinealon | Khavinson VKh, Kuznik BI, Tarnovskaya SI, Lin'kova NS. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Int J Mol Sci. 2021. PMC7795577. | mechanism / discovery |
| 2020 | Pinealon | Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis. Int J Mol Sci. 2020;21(2):609. PMID: 31963526. PMID 31963526 | mechanism / discovery |
| 2020 | Pinealon | Khavinson VKh, Kuznik BI, Trofimova SV, Lin'kova NS. Cortexin and its short peptides AEDG and EDR modulate gene expression of proteins in pathogenesis of Alzheimer's disease. Biomed Khim. 2020. (Parallel framework evidence for Khavinson short-peptide gene-expression paradigm.) | mechanism / discovery |
| 2015 | Pinealon | Ashapkin VV, Linkova NS, Khavinson VK, Vanyushin BF. Epigenetic Mechanisms of Peptidergic Regulation of Gene Expression during Aging of Human Cells. Biochemistry (Mosc). 2015;80(3):310-322. PMID: 25761684. PMID 25761684 | mechanism / discovery |
| 2022 | Pinealon | Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of aging: methodology and evidence. Bull Exp Biol Med. 2022. | bioregulator literature |
| 2020 | Pinealon | Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation, Proliferation, and Apoptosis. Adv Gerontol. 2020;10(2):98-106. | bioregulator literature |
| 2019 | Pinealon | Kolchina N, Khavinson V, Linkova N, Yakutseni P, Petukhov M, Morozova E, Ashapkin V. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Res. 2019;47(20):10553-10563. PMID: 31584079. PMID 31584079 | bioregulator literature |
| 2017 | Pinealon | Khavinson VKh, Sibarov DA, Tsai PY, Adushkin BV, Ryzhak GA. Short peptides stimulate serotonin release and attenuate hyperexcitation in the hippocampus. Bull Exp Biol Med. 2017;163(4):539-541. | bioregulator literature |
| 2008 | Selank | Zozulia AA, Neznamov GG, Syunyakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. (Russian Phase… PMID 18454096 | human trial, Phase 3 |
| 2015 | Selank | Medvedev VE, Teresh'chenko OE, Israelyan AY, et al. [Optimization of therapy with traditional anxiolytic drugs in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(4):33-40. | human study |
| 2008 | Selank | Uchakina ON, Uchakin PN, Miasoedov NF, et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. | human study |
| 2019 | Selank | Inozemtseva LS, Kudryavtseva NN, Bobkova NV, Dolotov OV, Gerasimova OA, Levitskaya NG, Kamensky AA, Andreeva LA, Myasoedov NF, Grivennikov IA. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus… PMID 31625062 | preclinical, in vivo |
| 2017 | Selank | Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Biomed Res Int. 2017;2017:2875904. PMC5322660. | preclinical, in vivo |
| 2008 | Selank | Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID: 18841778. PMID 18841778 | preclinical, in vivo |
| 2007 | Selank | Semenova TP, Medvinskaia NI, Nesterova IV, Kozlovskaia MM. [Experimental analysis of the effect of Selank on the emotional and cognitive behavior of mice]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2007;57(6):738-743. | preclinical, in vivo |
| 1998 | Selank | Seredenin SB, Kozlovskaia MM, Blednov IuA, Kozlovskii II. [Anxiolytic properties of Selank in BALB/c mice with differences in dopamine system reactivity]. Biull Eksp Biol Med. 1998;126(4):402-406. PMID: 9868709. PMID 9868709 | preclinical, in vivo |
| 2009 | Selank | Russian Federation State Register of Medicines. Selank — 0.15% intranasal solution. Approved 2009. | regulatory / registry |
| 2017 | Selank | Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, Limborska S, Myasoedov N, Pavlova G, Slominsky P, Shadrina M. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. PMID… PMID 28316569 | research article |
| 2016 | Selank | Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26903861. PMC4757669. PMID 26903861 | research article |
| 2003 | Selank | Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(7):639-643. PMID: 14552536. PMID 14552536 | research article |
Related pair pages
More research context
Frequently asked
Have Pinealon and Selank been studied together?
Researchers have published mechanistic-level co-administration discussion of Pinealon and Selank. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Pinealon and Selank share?
Pinealon and Selank do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Pinealon and Selank?
Pinealon: Not approved. Selank: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Pinealon and Selank?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Pinealon profile and the Selank profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026